Valuation : Neuland Laboratories Limited

Market Cap 302B 3.16B 2.72B 2.58B 2.34B 4.38B 4.41B 30.63B 11.78B 154B 11.87B 11.61B 485B P/E 2027 *
63.2x
P/E 2028 * 48.4x
Enterprise Value 305B 3.19B 2.75B 2.6B 2.36B 4.42B 4.44B 30.89B 11.88B 155B 11.97B 11.71B 490B EV / Sales 2027 *
12.5x
EV / Sales 2028 * 10.4x
Free-Float
62.26%
Yield 2027 *
0.1%
Yield 2028 * 0.13%
1 day-1.11%
1 week+3.86%
Current month+2.28%
1 month+4.55%
3 months+36.85%
6 months+87.17%
Current year+55.09%
1 week 22,415
Extreme 22415
24,225
1 month 22,415
Extreme 22415
24,225
Current year 11,500
Extreme 11500
24,225
1 year 11,500
Extreme 11500
24,225
3 years 3,522
Extreme 3522
24,225
5 years 967
Extreme 967
24,225
10 years 245.75
Extreme 245.75
24,225
Manager TitleAgeSince
Chief Executive Officer 47 31/03/2026
Director of Finance/CFO - 22/11/2022
Chief Tech/Sci/R&D Officer - 28/02/2023
Director TitleAgeSince
Director/Board Member 50 31/12/2001
Chairman 82 06/01/1984
Director/Board Member 47 28/02/2007
Change 5-day change 1-year change 3-year change Capi.($)
-1.11%+3.86% - - 3.16B
-0.65%-2.93%+47.70%+86.17% 994B
-0.29%-3.51%+49.15%+62.35% 640B
+0.83%+0.26%+17.76%+72.25% 454B
-0.38%-3.59%+30.13%+35.17% 337B
-0.09%-13.54%+13.34%+24.95% 261B
-0.43%-2.48%-0.73%+9.58% 246B
-1.34%-13.70%+36.53%+44.96% 204B
-3.44%-7.51%-20.63%-59.44% 190B
-0.75%-4.82%+25.46%+87.14% 178B
Average -0.77%-5.76%+22.08%+40.35% 389.42B
Weighted average by Cap. -0.51%-4.42%+30.96%+54.95%

Financials

2027 *2028 *
Net sales 24.43B 256M 220M 209M 189M 355M 357M 2.48B 953M 12.43B 961M 939M 39.28B 29.27B 306M 264M 250M 227M 425M 427M 2.97B 1.14B 14.89B 1.15B 1.13B 47.05B
Net income 4.8B 50.23M 43.27M 40.98M 37.14M 69.68M 70.03M 487M 187M 2.44B 189M 184M 7.71B 6.26B 65.57M 56.5M 53.5M 48.49M 90.97M 91.43M 635M 244M 3.19B 246M 241M 10.07B
Net Debt 2.56B 26.81M 23.1M 21.87M 19.82M 37.19M 37.38M 260M 99.89M 1.3B 101M 98.47M 4.12B 979M 10.25M 8.83M 8.36M 7.58M 14.22M 14.29M 99.33M 38.2M 498M 38.5M 37.66M 1.57B
Logo Neuland Laboratories Limited
Neuland Laboratories Ltd. is a global provider of active pharmaceutical ingredients (APIs) contract development and manufacturing organization (CDMO) services. It is focused on manufacture and sale of active pharmaceutical ingredients and allied services. It supports biotechnology and pharmaceutical companies in the design, development and manufacturing of complex APIs. It has two business verticals: generic drug substances (GDS) and custom manufacturing solutions (CMS). It develops and manufactures non-exclusive APIs both Prime APIs comprising large volume, mature molecules, and specialty APIs comprising lower volume, complex molecules with less competition. It develops small molecules and peptides for clinical trials and beyond. It provides an end-to-end continuum of customized services from early-stage drug development (Pre-IND) through to commercial manufacturing of complex APIs, including process development, process optimization, analytical testing, and regulatory support.
Employees
2,183
Date Price Change Volume
11/09/26 ₹23,535.00 -1.11% 43,901
10/09/26 ₹23,800.00 +2.61% 55,257
09/09/26 ₹23,195.00 -3.33% 57,976
08/09/26 ₹23,995.00 +4.92% 82,211
07/09/26 ₹22,870.00 +0.93% 22,291
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
23,536.20INR
Average target price
24,334.75INR
Spread / Average Target
+3.39%

Quarterly revenue - Rate of surprise

40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!